Hans Johan Hekland

Rieber & Son AS produces exports and supplies food products to the food service market and other food manufacturers. Its brands include Toro, Vitana, Delecta, Denja, Vetslands Lefsa, Mr. Lee, and Vossafår. Its business units are divided into three segments which reflect the main markets in which it operates. The operating segments are Western Europe, Central Europe and Russia/Others. The Western Europe segment comprises Norway, Denmark, Sweden, Germany, Benelux, the United States of America and the United Kingdom. The Central Europe segment is composed of Czech Republic, Slovakia and Poland. The Russia/Other segment produce and sell nuts in the market. The company was founded by Paul Gottlieb Rieber in 1839 and is headquartered in Bergen, Norway.

Novel Diagnostics AS provides biomedical research and diagnostics development services. It sells and develops medical and diagnostic products and drives commercialization of research results. The firm also invests in securities; either in form of follow-up investments in companies already has invested in, or as part of other strategic investments. The company was founded on June 10, 2002 and is headquartered in Bergen, Norway.

DnB NOR Finans AS is based in Bergen, Norway. DnB NOR Finans AS provides financial services.

Sarsia Venture Management AS (SVM) is a venture capital advisory and management firm based in Bergen, Norway. They manage and advise the Sarsia Life Science Fund, established in 2005, which focuses on life science and biotechnology opportunities in the Nordic region.

ScreenCancer AS offers cancer screening and diagnostic program to the public. It provides a panel of screening tests for several major cancers such as colorectal, bladder, breast, prostate, skin, and lung. The company was founded by Christian Horn and Dagfinn Steinar Ogreid in 2007 and is headquartered in Sola, Norway.

Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway.